Home|Journals|Articles by Year|Audio Abstracts

Case Report

Clindamycin as single therapy for cerebral toxoplasmosis HIV in the history of sulfa allergy: A Case Report

Tommy Sarongku,Gede Ariswanda,I Ketut Sumada,Ni Ketut Wiratni,I Putu Eka Widyadharma.

Cited by 0 Articles

Cerebral toxoplasmosis is an opportunistic infection in HIV with CD4 T-cells below < 200/uL. The aetiology is Toxoplasma gondii. Trimethoprim plus sulfamethoxazole (cotrimoxazole) combined pyrimethamine is the first line for the treatment of cerebral toxoplasmosis in immunodeficiency. The second line for treatment is clindamycin combined pyrimethamine in Indonesia.
We reported a 48-year-old woman as diagnosed retroviral infection referred to Wangaya General Hospital, with main complaints of vomiting and severe headache. The blood test showed normal limits except lymphocyte account. IgM antibody for toxoplasmosis raised. Brain computed tomography-scan showed a cystic lesion in right basal ganglia with ring-enhancing surrounding by finger-like oedema. She treated with pyrimethamine and cotrimoxazole. The patient had a reddish rash on the skin with thrombocytopenia during 7-day on treatment suspected sulfa and pyrimethamine adverse side effect. Patient treated clindamycin as single therapy for cerebral toxoplasmosis. Her headache is better within two weeks of admission. Thirty days later the patient was repeated brain-CT scan, and the mass was found to be smaller.
Conclusions: Single-therapy with clindamycin in CNS toxoplasmosis showed good outcome in resource-poor setting and history of sulfonamide allergy.

Key words: HIV, Cerebral toxoplasmosis, Clindamycin, Sulfa Allergy

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.